Are peptides legal? FDA status in 2026, explained

Three routes, three answers

Most of the peptides people search for, including BPC-157, TB-500 and KPV, are not FDA-approved drugs. Their legal status turns on compounding rules and on how they are sold.

How compounding rules work

Section 503A of the Federal Food, Drug, and Cosmetic Act covers compounding by state-licensed pharmacies for individual patients. A 503A pharmacy may generally compound from a bulk drug substance only if it has a USP monograph, is a component of an FDA-approved drug, or appears on the FDA's "503A bulks list".

While nominated substances are being evaluated for that list, the FDA sorts them into interim categories:

The Pharmacy Compounding Advisory Committee (PCAC) reviews substances and votes on whether to recommend them for the 503A bulks list. Its votes are advice to the FDA; the list changes only when the FDA finalizes it.

What changed in 2026

The 12 peptides removed from Category 2 on 15 Apr 2026 include BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, DSIP, injectable GHK-Cu, LL-37, Melanotan II, dihexa and PEG-MGF.

The July 2026 PCAC votes

The vote tallies above come from the National Community Pharmacists Association's report of the meeting; the FDA's meeting page is the primary record of the meeting, and we have not found a primary tally. None of these votes had been finalized by the FDA at the time of writing. Until the FDA acts, compounding status for these peptides should be treated as unsettled. The legal tracker records the next step for each one, with its source, as it happens.

"Research use only" products

Research-labelled peptides are sold with a disclaimer that they are not for human use. That label does not make marketing them for people legal. On 24 Aug 2026 the FDA sent warning letters to five sellers of research peptides. We list the action, with its date and source, in the legal tracker.

Investigational drugs such as retatrutide are a special case. Retatrutide is still in clinical trials and is not approved for any use; products sold online under its name are not the trial drug and have no reviewed quality data. See our retatrutide explainer.

Sport and anti-doping

Legal to buy is not the same as allowed in competition. The World Anti-Doping Agency prohibits BPC-157 under section S0 (non-approved substances), and TB-500 is also prohibited. Athletes subject to testing should check the current WADA Prohibited List and their own federation's rules.

Outside the United States

Everything above describes US federal rules. Other regulators, such as the UK's MHRA, Australia's TGA and Health Canada, set their own rules, and US state law can add more. On 2 Oct 2026 we searched the FDA, the UK emc compendium, Health Canada's Drug Product Database, the EMA's list of centrally authorised medicines and the Australian ARTG for each peptide we cover. Those records show only whether an approved product exists in each place. They do not say whether a peptide is legal to import, compound or possess there, and we have no primary-source summary of those rules by country. Government actions we have sourced include Health Canada's permanent injunction against an injectable-peptide seller (29 Jul 2026) and the TGA's June 2026 statement making unapproved peptide products a compliance priority. Start from the legal hub.